Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Medivation Gets Hostile After Sanofi's "Misleading" Maneuvers

Executive Summary

The biotech continues to reject offers from the French pharma and lays out the problems it has with the offer to shareholders. Meanwhile, Sanofi has taken its bid hostile and pushes to replace the biotech's board.

Advertisement

Related Content

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations
Tesaro Doubles On Super NOVA Data, Lifts PARP Competitors
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected
Sanofi Earnings Emphasize Need For Medivation Buy
Sanofi Goes Public With Hostile Medivation Bid

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register